Thrombotic-thrombocytopenic purpura;Thrombotisch-thrombozytopenische purpura

Internist

Volumn 51, Issue 9, 2010, Pages 1136-1144

  Hellmann, M ^a   Hallek, M ^a   Scharrer, I ^b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Plasmapheresis; Rituximab; Thrombocytopenia; Thrombotic microangiopathies; von Willebrand factor

Indexed keywords

ADAMTS1 PROTEIN; METALLOPROTEINASE; VON WILLEBRAND FACTOR;

ARTERIOLE; GENE MUTATION; HEADACHE; PLASMAPHERESIS; PROTEIN DEFICIENCY; REVIEW; THROMBOCYTE; THROMBOCYTOPENIA; THROMBOCYTOPENIC PURPURA; VON WILLEBRAND DISEASE;

ACUTE DISEASE; ADAM PROTEINS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AUTOANTIBODIES; DNA MUTATIONAL ANALYSIS; GENOTYPE; HUMANS; IMMUNOLOGIC FACTORS; PLASMA EXCHANGE; PLASMAPHERESIS; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RECURRENCE;

EID: 77957799830     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-010-2599-0     Document Type: Review

References (34)

1. Bandarenko N, Brecher ME (1998) United States Thrombotic Thrombocytopenic Purpura Apheresis Study Group (US TTP ASG): multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange. J Clin Apher 13:133-141
2. Braun N, Risler T (2007) Therapeutische Apherese. In: Schölmerich J (Hrsg) Medizinische Therapie 2007/2008, 3. Aufl. Springer, Berlin Heidelberg New York, S 205-206
3. Chemnitz JM, Uener J, Hallek M, Scheid C (2010) Long-term follow-up of idiopathic thrombotic thrombocytopenic purpura treated with rituximab. Ann Hematol [Epub ahead of print]
4. Cohen JA, Brecher ME, Bandarenko N (1998) Cellular source of serum lactate dehydrogenase elevation in patients with thrombotic thrombocytopenic purpura. J Clin Apher 13:16-19
5. Coppo P, Veyradier A (2009) Thrombotic microangiopathies: towards a pathophysiology-based classification. Cardiovasc Hematol Disord Drug Targets 9:36-50
6. Crowther MA, Heddle N, Hayward CP et al (1996) Splenectomy done during hematologic remission to prevent relapse in patients with thrombotic thrombocytopenic purpura. Ann Intern Med 125:294-296
7. Fakhouri F, Vernant JP, Veyradier A et al (2005) Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood 106:1932-1937
8. Foley SR, Webert K, Arnold DM et al; Members of the Canada Apheresis Group (2009) A Canadian phase II study evaluating the efficacy of rituximab in the management of patients with relapsed/refractory thrombotic thrombocytopenic purpura. Kidney Int Suppl 112:S55-S58
9. George JN (2000) How I treat patients with thrombotic thrombocytopenic purpura - hemolytic uremic syndrome. Blood 96:1223-1229
10. George JN, Woodson RD, Kiss JE et al (2006) Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disorders. J Clin Apher 21:49-56
11. Gerritsen HE, Robles R, Lammle B, Furlan M (2001) Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood 98:1654-1661
12. Hawkins BM, Abu-Fadel M, Vesely SK, George JN (2008) Clinical cardiac involvement in thrombotic thrombocytopenic purpura: a systematic review. Transfusion 48:382-392
13. Heidel F, Lipka DB, Auer C von et al (2007) Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia. Thromb Haemost 97:228-233
14. Henon P (1991) Treatment of thrombotic thrombopenic purpura. Results of a multicenter randomized clinical study. Presse Med 20:1761-1767
15. Hovinga JA, Vesely SK, Terrell DR et al (2010) Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 115:1500-1511
16. Illner N, Wolf G (2010) Rituximab as effective therapy in very severe thrombotic thrombocytopenic purpura (TTP). Dtsch Med Wochenschr 135:71-74
17. Kasper S, Neurath MF, Huber C et al (2007) Protein A immunoadsorption therapy for refractory, mitomycin C-associated thrombotic microangiopathy. Transfusion 47:1263-1267
18. Kiss JE (2010) Thrombotic thrombocytopenic purpura: recognition and management. Int J Hematol 91:36-45
19. Lotta LA, Garagiola I, Palla R et al (2010) ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura. Hum Mutat 31:11-19
20. McDonald V, Manns K, Mackie IJ et al (2010) Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost [Epub ahead of print]
21. Moake JL, Rudy CK, Troll JH et al (1982) Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 307:1432-1435
22. Moschcowitz E (1952) An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries; an undescribed disease. Am J Med 13:567-569
23. Peyvandi F, Lavoretano S, Palla R et al (2008) ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica 93:232-239
24. Rieger M, Mannucci PM, Kremer Hovinga JA et al (2005) ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood 106:1262-1267
25. Rock GA, Shumak KH, Buskard NA et al (1991) Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 325:393-397
26. Sadler JE (2008) Von Willebrand factor, ADAMTS13 and thrombotic thrombocytopenic purpura. Blood 112:11-18
27. Scully M, Yarranton H, Liesner R et al (2008) Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features. Br J Haematol 142:819-826
28. Tsai HM (2010) Pathophysiology of thrombotic thrombocytopenic purpura. Int J Hematol 91:1-19
29. Upshaw JD (1978) Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia. N Engl J Med 298:1350-1352
30. Vesely SK, George JN, Lammle B et al (2003) ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 102:60-68
31. Yomtovian R, Niklinski W, Silver B et al (2004) Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature. Br J Haematol 124:787-795
32. Zheng X, Chung D, Takayama TK et al (2001) Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 276:41059-41063
33. Zheng XL, Kaufman RM, Goodnough LT, Sadler JE (2004) Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood 103:4043-4049
34. Zheng XL, Sadler JE (2008) Pathogenesis of thrombotic microangiopathies. Annu Rev Pathol 3:249-277